Historic overview and recent advances in the synthesis of super-statins

Current Organic Chemistry

Volumn 14, Issue 8, 2010, Pages 816-845

  Časar, Zdenko ^a  

^a Organic Synthesis Department   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CHAINS; ORGANIC COMPOUNDS;

ECO-FRIENDLY; FUNGAL METABOLITES; HEPTANOIC ACID; PHARMACEUTICAL SECTOR; SIDE-CHAINS; STATINS; STRUCTURAL MODIFICATIONS; SYNTHETIC STRATEGIES; THERAPEUTIC APPLICATION; THERAPEUTIC CLASS;

SYNTHESIS (CHEMICAL);

EID: 77954940183     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/138527210791111858     Document Type: Article

References (131)

1. Davidson, M.H.; Robinson, J.G. Lipid-lowering effects of statins: a comparative review. Expert Opin. Pharmacother., 2006, 7, 1701-1714.
2. Kidd, J. Life after statin patent expiries. Nat. Rev. Drug Discov., 2006, 5, 813-814.
3. Istvan, E.S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 2001, 292, 1160-1164.
4. Tobert, J.A. Lovastatin and beyond: the history of the HMG-COA reductase inhibitors. Nat. Rev. Drug Discov., 2003, 2, 517-526.
5. Bhatnagar, D.; Soran, H.; Durrington, P.N. Hypercholesterolaemia and its management. BMJ, 2008, 337, 503-508.
6. Chopra, V.; Choksi, P.U.; Cavusoglu, E. Beyond lipid lowering: the anti- hypertensive role of statins. Cardiovasc. Drugs Ther., 2007, 21, 161-169.
7. Ludman, A.; Venugopal, V.; Yellon, D.M.; Hausenloy, D.J. Statins and cardioprotection-More than just lipid lowering? Pharmacol. Ther., 2009, 122, 30-43.
8. Tziomalos, K.; Kakafika, A.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. The role of statins for the primary and secondary prevention of coronary heart disease in women. Curr. Pharm. Des., 2009, 15, 1054-1062.
9. Switzer, J.A.; Hess, D.C. Statins in stroke: prevention, protection and recovery. Expert Rev. Neurother., 2006, 6, 195-202.
10. Bersano, A.; Ballabio, E.; Lanfranconi, S.; Mazzucco, S.; Candelise, L.; Monaco, S. Statins and stroke. Curr. Med. Chem., 2008, 15, 2380-2392.
11. Young, R.P.; Hopkins, R.; Eaton, T.E. Potential benefits of statins on mor- bidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad. Med. J., 2009, 85, 414-421.
12. Liao, J.K. Statins: potent vascular anti-inflammatory agents. Int. J. Clin. Pract., 2004, 58, 41-48.
13. Sleijfer, S.; van der Gaast, A.; Planting, A.S.; Stoter, G., Verweij, J. The potential of statins as part of anti-cancer treatment. Eur. J. Cancer, 2005, 41, 516-522.
14. Stoll, L.L.; McCormick, M.L.; Denning, G.M.; Weintraub, N.L. Antioxidant effects of statins. Drugs Today, 2004, 40, 975-990.
15. Watanabe, T.; Yasunari, K.; Nakamura, M. Antioxidative actions of statins: potential mechanisms for antiathersclerotic effects. Mini Rev. Med. Chem., 2006, 6, 505-508.
16. Paraskevas, K.I.; Tzovaras, A.A.; Briana, D.D.; Mikhailidis, D.P. Emerging indications for statins: a pluripotent family of agents with several potential applications. Curr. Pharm. Des., 2007, 13, 3622-3636.
17. Lahera, V.; Goicoechea, M.; de Vinuesa, S.G.; Miana, M.; de las Heras, N.; Cachofeiro, V.; Luño, J. Endothelial dysfunction, oxidative stress and in- flammation in atherosclerosis: beneficial effects of statins. Curr. Med. Chem., 2007, 14, 243-248.
18. Endo, A.; Kuroda, M.; Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by penicillium citrinum. J. Antibiot., 1976, 29, 1346-1348.
19. Endo, A.; Tsujita, Y.; Kuroda, M.; Tanzawa, K. Inhibition of cholesterol-synthesis invitro and invivo by ML-236A and ML-236B, competitive inhibi- tors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Eur. J. Biochem., 1977, 77, 31-36.
20. Alberts, A.W.; Chen, J.; Kuron, G.; Hunt, V.; Huff, J.; Hoffman, C.; Rothrock, J.; Lopez, M.; Joshua, H.; Harris, E.; Patchett, A.; Monaghan, R.; Currie, S.; Stapley, E.; Albers-Schonberg, G.; Hensens, O.; Hirshfield, J.; Hoogsteen, K.; Liesch, J.; Springer, J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme-A reductase and a cholesterol- lowering agent. Proc. Natl. Acad. Sci. U.S.A., 1980, 77, 3957-3961.
21. Tsujita, Y.; Kuroda, M.; Shimada, Y.; Tanzawa, K.; Arai, M.; Kaneko, I.; Tanaka, M.; Masuda, H.; Tarumi, C.; Watanabe, Y. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-a reductase - tissue- selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta, 1986, 877, 50-60.
22. Hoffman, W.F.; Alberts, A.W.; Anderson, P.S.; Chen, J.S.; Smith, R.L.; Willard, A.K. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side-chain ester derivatives of mevinolin. J. Med. Chem., 1986, 29, 849-852.
23. Sit, S.Y.; Parker, R.A.; Motoc, I.; Han, W.; Balasubramanian, N.; Catt, J.D.; Brown, P.J.; Harte, W.E.; Thompson, M.D.; Wright, J.J. Synthesis, biologi- cal profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. J. Med. Chem., 1990, 33, 2982-2999.
24. Tse, F.L.S.; Smith, H.T.; Ballard, F.H.; Nicoletti, J. Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey. Biopharm. Drug Dispos., 1990, 11, 519-531.
25. Ferguson, E.; Mcnally, W.; Bocan, T.M.A.; Uhlendorf, P.D.; Krause, B.R.; Sliskovic, D.R.; Obrien, P.; Roth, B.D.; Newton, R.S. Measurement of sterol synthesis and tissue distribution of a liver selective HMG-COA reductase inhibitor, CI-981. FASEB J., 1991, 5, A1253-A1253.
26. Quirk, J.; Thornton, M.; Kirkpatrick, P. Fresh from the pipeline - Rosuvastatin calcium. Nat. Rev. Drug Discov., 2003, 2, 769-770.
27. Kajinami, K.; Mabuchi, H.; Saito, Y. NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin. Invest. Drugs, 2000, 9, 2653-2661.
28. Kuhlmann, J.; Muck, W.; Bischoff, H.; von Keutz, E.; Llewellyn, M. Ceri- vastatin (BAY w 6228): a novel HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev., 1998, 16, 236-263.
29. Furberg, C.D.; Pitt, B. Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc. Med., 2001, 2, 205-207.
30. Endo, A. The discovery and development of HMG-COA reductase inhibitors. J. Lipid Res. 1992, 33, 1569-1582.
31. Endo, A.; Hasumi, K. HMG-CoA reductase inhibitors. Nat. Prod. Rep., 1993, 10, 541-550.
32. Miyachi, N.; Suzuki, M.; Ohara, Y.; Hiyama, T. Syntheses of HMG-COA reductase inhibitors. J. Synth. Org. Chem. Jpn. 1995, 53,186-196.
33. Repi, O.; Prasad, K.; Lee, G.T. The story of Lescol: from research to production. Org. Process Res. Dev., 2001, 5, 519-527.
34. Roth, B.D. In: Progress in Medicinal Chemistry; King, F.D.; Oxford, A.W. Eds.; Elsevier Science B.V: Amsterdam, 2002; Vol. 40, pp. 1-22.
35. Li, J.J.; Johnson, D.S.; Sliskovic, D.R.; Roth, B.D. Contemporary Drug Synthesis; John Wiley & Sons Inc.: Hoboken, New Jersey, 2004; pp. 113-124.
36. Hajkova, M.; Kratochvila, B.; Radl, S. Atorvastatin-the world's best selling drug. Chem. Listy, 2008, 102, 3-14.
37. Müller, M. Chemoenzymatic synthesis of building blocks for statin side chains. Angew. Chem., Int. Ed. 2005, 44, 362-365.
38. Liljeblad, A.; Kallinen, A.; Kanerva, L.T. Biocatalysis in the preparation of the statin side chain. Curr. Org. Synth., 2009, 6, 362-379.
39. Soriente, A.; De Rosa, M.; Stanzione, M.; Villano, R.; Scettri, A. An effi- cient asymmetric aldol reaction of Chan's diene promoted by chiral Ti(IV)- BINOL complex. Tetrahedron Asymmetry, 2001, 12, 959-963.
40. Hirai, K.; Ishiba, T.; Koike, H.; Watanabe, M. Pyrimidine derivatives as HMG-CoA reductase inhibitors. Eur. Pat. Appl. EP 521471, January 7, 1993.
41. Okada, T.; Konoike, T. Preparation of pyrimidine derivatives. Jpn. Kokai Tokkyo Koho JP 07118233, September 5, 1995.
42. Kumar, Y.; De, S.; Rafeeq, M.; Meeran, H.N.P.N.; Sathyanarayana, S. Process for the preparation of rosuvastatin. PCT Pat. Appl. WO 2003/097614, November 27, 2003.
43. Niddam-Hildesheim, V.; Chen, K. A process for the preparation of rosuvas- tatin involving a TEMPO-mediated oxidation step. PCT Pat. Appl. WO 2006/017357, February 16, 2006.
44. Anderson, P.L. Mevalonolactone analogs and their pharmaceutical composi- tions. PCT Pat. Appl. WO 84/02903, August 2, 1984.
45. Beck, G.; Kesseler, K.; Baader, E.; Bartmann, W.; Bergmann, A.; Granzer, E.; Jendralla, H.; Kerekjarto, B.v.; Krause, R.; Paulus, E.; Schubert, W.; Wess, G. Synthesis and biological activity of new HMG-CoA reductase in- hibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy- 6-heptenoic (-heptanoic) acids. J. Med. Chem., 1990, 33, 52-60.
46. Jendralla, H.; Granzer, E.; von Kerekjarto, B.; Krause, R.; Schacht, U.; Baader, E.; Bartmann, W.; Beck, G.; Bergmann, A.; Kesseler, K.; Wess, G.; Chen, L.-J.; Granata, S.; Herchen, J.; Kleine, H.; Schüssler, H.; Wagner, K. Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J. Med. Chem., 1991, 34, 2962-2983.
47. Chan, C.; Bailey, E.J.; Hartley, C.D.; Hayman, D.F.; Hutson, J.L.; Ingalis, G.G.A.; Jones, P.S.; Keling, S.E.; Kirk, B.E.; Lamont, R.B.; Lester, M.G.; Prithard, J.M.; Barry, C.P.; Scicinski, J.J.; Spooner, S.J.; Smith, G.; Steeples, I.P.; Watson, N.S. Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7- (N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of 3-hydroxy- 3-methylglutarate-CoA reductase inhibitors. J. Med. Chem., 1993, 36, 3646-3657.
48. Yang, Y.L.; Falck, J.R. Mevinic acids and analog: preparation of a key chiral intermediate. Tetrahedron Lett., 1982, 23, 4305-4308.
49. Wareing, J.R. (Tetrahydropyran-2-yl) aldehydes. U.S. Patent 4,474,971, October 2, 1984.
50. Rosen, T.; Taschner, M.J.; Heathcock, C.H. Synthetic and biological studies of compactin and related compounds. 2. Synthesis of the lactone moiety of compactin. J. Org. Chem., 1984, 49, 3994-4003.
51. Kozikowski, A.P.; Li, C.-S. A nitrile oxide based entry to 2,3-dihydropyran4-ones. Synthesis of a protected version compactin lactone in racemic and optically active forms. J. Org. Chem. 1985, 50, 778-785.
52. Jewell, C.F.Jr.; Wareing, J.R. 4-Trisubstituted silyloxy-6-oxotetrahydropyran-2-yl-aldehyde intermediates. U.S. Patent 4,625,039, November 25, 1986.
53. Barth, M.; Bellamy, F.D.; Renaut, P.; Samreth, S.; Schuber, F. Towards a new type-of HMG-COA reductase inhibitor. Tetrahedron, 1990, 46, 6731-6740.
54. Mash, E.A.; Arterburn, J.B.; Nimkar, S.K. Synthesis of a Mevinic Acid Lactone Precursor. J. Carbohydr. Chem., 1992, 11, 415-424.
55. Valverde, S.; Lopez, J.C.; Gomez, A.M.; Garcia-Ochoa, S. Practical synthesis of an enantiomerically pure intermediate of the lactone moiety of mevinic acids. J. Org. Chem., 1992, 57, 1613-1615.
56. Boquel, P.; Taillefumier, C.; Chapleur, Y.; Renaut, P.; Samreth, S.; Bellamy, F.D. Towards a new type of HMG-CoA reductase inhibitors: Part II: Dramatic substituents effects in the C-5 epimerisation of carbohydrate derivatives. Tetrahedron, 1993, 49, 83-96.
57. Durand-Reville, T.; Gobbi, L.B.; Gray, B.L.; Ley, S.V.; Scott, J.S. Highly selective entry to the azadirachtin skeleton via a Claisen rearrange-ment/radical cyclization sequence. Org. Lett., 2002, 4, 3847-3850.
58. Tararov, V.I.; Andrushko, N.; Andrushko, V.; König, G.; Spannenberg, A.; Börner, A. Synthesis of the chiral side chain of statins-lactone versus lactol pathway. Euro. J. Org. Chem., 2006, 5543-5550.
59. Liar, M. Process for the synthesis of rosuvastatin calcium using L-malic acid for the side chain chirality. PCT Pat. Appl. WO 2007/017117, February 15, 2007.
60. Takahashi, K.; Minami, T.; Ohara, Y.; Hiyama, T. A new synthesis of HMG- CoA reductase inhibitor NK-104 through hydrosilylation-cross coupling re- action. Tetrahedron Lett., 1993, 34, 8263-8266.
61. Takahashi, K.; Minami, T.; Ohara, Y.; Hiyama, T. Synthesis of an artificial HMG-CoA reductase inhibitor NK-104 via a hydrosilylation-cross-coupling reaction. Bull. Chem. Soc. Jpn., 1995, 68, 2649-2656.
62. Castro, J.; Coteron, J.M.; Fraile, M.T.; Garcia-Ochoa, S.; Gomez de las Heras, F.; Martin-Cuesta, A. A new synthesis of 3,5-dihydroxy-7-(1- pyrrolyl)-6-heptenoic acids, a family of HMGCoA reductase inhibitors with antifungal activity. Tetrahedron Lett., 2002, 43, 1851-1854.
63. Oehrlein, R.; Baisch, G.; End, N.; Burkhardt, S.; Studer, M. Process for the preparation of 7-amino 3,5-dihydroxy heptanoic acid derivatives as interme- diates useful in the synthesis of statin derivatives. PCT Pat. Appl. WO 2003/004450, January 16, 2003.
64. Wolleb, H.; Wolleb, A.; Van Der Schaaf, P.A.; Kolly, R.; End, N. Process for the preparation of indole derivatives. PCT Pat. Appl. WO 2003/018555, March 6, 2003.
65. Hiyama, T.; Minami, T.; Takahashi, K.; Miyachi, N.; Ohara, Y. Preparation of 6-heptynoic and heptenoic acid compounds as intermediates for HMG- CoA reductase inhibitors. PCT Pat. Appl. WO 94/06746, March 03, 1994.
66. Rosen, T.; Heathcock, C.H. Synthetic and biological studies of compactin and related compounds. 4. Total synthesis of (+)-compactin. J. Am. Chem. Soc., 1985, 107, 3731-3733.
67. Heathcock, C.H.; Hadley, C.R.; Rosen, T.; Theisen, P.D.; Hecker, S.J. Total synthesis and biological evaluation of structural analogs of compactin and dihydromevinolin. J. Med. Chem., 1987, 30, 1858-1873.
68. Theisen, P.D.; Heathcock, C.H. Improved procedure for preparation of optically active 3-hydroxyglutarate monoesters and 3-hydroxy-5-oxoalkanoic acids. J. Org. Chem., 1988, 53, 2374-2378.
69. Karanewsky, D.S.; Malley, M.F.; Goudoutas, J.Z. Practical synthesis of an enantiomerically pure synthon for the preparation of mevinic acid analogs. J. Org. Chem., 1991, 56, 3744-3747.
70. Konoike, T.; Araki, Y. Practical synthesis of chiral synthons for the preparation of HMG-CoA reductase inhibitors. J. Org. Chem., 1994, 59, 7849-7854.
71. Acemoglu, M.; Brodbeck, A.; Garcia, A.; Grimier, D.; Hassel, M.; Riss, B.; Schreiber, R. A new and efficient synthesis of the HMG-CoA reductase in- hibitor pitavastatin. Helv. Chim. Acta, 2007, 90, 1069-1081.
72. Korostylev, A.; Andrushko, V.; Andrushko, N.; Tararov, V.I.; König, G.; Börner, A. Highly enantioselective hydrogenation of ethyl 5,5-dimethoxy-3- oxopentanoate and its application for the synthesis of a statin precursor. Eur. J. Org. Chem., 2008, 840-846.
73. Wess, G.; Kesseler, K.; Baader, E.; Bartmann, W.; Beck, G.; Bergmann, A.; Jendralla, H.; Bock, K.; Holzstein, G.; Kleine, H.; Schnierer, M. Stereoselec- tive synthesis of HR 780 a new highly potent HMG-CoA reductase inhibitor. Tetrahedron Lett., 1990, 31, 2545-2548.
74. Kizaki, N.; Yamada, Y.; Yasohara, Y.; Nishiyama, A.; Miyazaki, M.; Mitsuda, M.; Kondo, T.; Ueyama, N.; Inoue, K. Process for the preparation of optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl]acetic acid derivatives. PCT Pat. Appl. WO 00/08011, February 17, 2000.
75. Cardani, S.; Scolastico, C.; Villa, R. Synthesis of enantiomeric pure intermediate for the lactone portion of compactin and mevinolin. Tetrahedron, 1990, 46, 7283-7288.
76. Choi, H.; Shin, H. Efficient synthesis of (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative as a chiral side chain of statins. Synlett, 2008, 1523-1525.
77. Wess, G.; Kesseler, K.; Baader, E.; Beck, G. Method for the preparation of optically active antihypercholesterolemic 3-desmethylmevalonic acids and lactone derivatives and intermediate compounds. Euro Pat. Appl. EP 0319847, June 14, 1989.
78. Radl, S. A new way to tert-butyl [(4R,6R)-6-aminoethyl-2,2-dimethyl-1,3- dioxan-4-yl]acetate, a key intermediate of atorvastatin synthesis. Synth. Commun., 2003, 33, 2275-2283.
79. Bratton, L.D.; Miller, S.R.; Pfefferkorn, J.A.; Sorenson, R.J.; Song, Y.; Sun, K.-L.; Trivedi, B.K.; Unangst, P.C.; Cheng, X.-M.; Lee, C.; Poel, T.-J. Preparation of hypocholesterolemic and hypolipidemic N-alkyl pyrroles as HMG-CoA reductase inhibitors. PCT Pat. Appl. WO 2005/056004, June 23, 2005.
80. Szpilman, A.M.; Cereghetti, D.M.; Wurtz, N.R.; Manthorpe, J.M.; Carreira, E.M. Synthesis of 35-deoxy amphotericin B methyl ester: a strategy for mo- lecular editing. Angew. Chem. Int. Ed., 2008, 47, 4335-4338.
81. Joshi, N.S.; Khile, A.S.; Kajale, Y.B.; Kamble, H.H. Process for the prepara- tion of 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl- amino)-5-pyrimidinecarbox-aldehyde and tert-butyl 2-[(4R,6S)-6-formyl-2,2- dimethyl-1,3-dioxan-4-yl]-acetate, key intermediates of rosuvastatin. PCT Pat. Appl. WO 2008/059519, May 22, 2008.
82. Minami, T.; Takahashi, K.; Hiyama, T. Stereoselective reduction of, - diketo esters derived from tartaric acid. A facile route to optically active 6- oxo-3,5-syn-isopropylidenedioxyhexanoate, a versatile synthetic intermediate of artificial HMG Co-A reductase inhibitors. Tetrahedron Lett., 1993, 34, 513-516.
83. Balasubramanian, N.; Brown, P.J.; Catt, J.D.; Han, W.T.; Parker, R.A.; Sit, S.Y.; Wright, J.J. A potent, tissue-selective, synthetic inhibitor of HMG-CoA reductase. J. Med. Chem., 1989, 32, 2038-2041.
84. Brower, P.L.; Butler, D.E.; Deering, C.F.; Le, T.V.; Millar, A.; Nanninga, T.N.; Roth, B.D. The synthesis of (4R-cis)-1,1-dimethylethyl 6- cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG- CoA reductase. Tetrahedron Lett., 1992, 33, 2279-2282.
85. Baumann, K.L.; Butler, D.E.; Deering, C.F.; Mennen, K.E.; Millar, A., Nanninga, T.N.; Palmer, C.W.; Roth, B.D. The convergent synthesis of CI- 981, an optically active, highly potent, tissue selective inhibitor of HMG- CoA reductase. Tetrahedron Lett., 1992, 33, 2283-2284.
86. Radl, S.; Stach, J.; Hajicek, J. An improved synthesis of 1,1-dimethylethyl 6- cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for atorvastatin synthesis. Tetrahedron Lett., 2002, 43, 2087-2090.
87. Baader, E.; Wess, G.; Weber, M.; Teetz, V.; Saric, R.; Schussler, H.; Bartmann, W.; Fehlhaber, H.-W.; Bergmann, A.; Beck, G.; Kesseler, K.; Jen- dralla, H. Syntheses of 4(R)-silyloxy-6(S)-iodomethyl-tetrahydropyran-2-one and its enantiomer, building blocks for HMG-COA reductase inhibitors. Tetrahedron Lett., 1988, 29, 2563-2565.
88. Bennett, F.; Knight D.W.; Fenton, G. Methyl (3R)-3-hydroxyhex-5-enoate as a precursor to chiral mevinic acid analog. J. Chem. Soc. Perkin Trans. 1, 1991, 133-140.
89. asar, Z. Straightforward and efficient synthesis of (4R,6S)-4-(tert- butyldimethylsilyloxy)-6-(hydroxymethyl)tetrahydropyran-2-one. Synlett 2008, 2036-2040.
90. Tang, J.; Brackenridge, I.; Roberts, S.M.; Beecher, J.; Willetts, A.J. Bakers' yeast oxidation of methyl para-tolylsuifide: Synthesis of a chiral intermediate in the preparation of the mevinic acid-type hypocholestemic agents. Tetrahedron, 1995, 51, 13217-13238.
91. Kalkote, U.R.; Ghorpade, S.R.; Chavan, S.P.; Ravindranathan, T. Simple, efficient chemoenzymatic synthesis of (S)-5-(tert-butyldimethylsilyloxy)-2- cyclohexenone and enantiomeric ketone intermediates of 19-nor-1,25-dihydroxyvitamin D3. J. Org. Chem., 2001, 66, 8277-8281.
92. Ghorpade, S.R.; Kalkote, U.R.; Chavan, S.P.; Bhide, S.R.; Ravindranathan, T.; Puranik, V.G. Efficient synthesis of optically pure (4R,6S)-4-(tert-butyldimethylsilyloxy)-6-(hydroxymethyl)tetrahydropyran-2-one and its enantiomer. J. Org. Chem., 2001, 66, 6803-6806.
93. asar, Z.; Komrlj J. The first convenient entry to -formyl- -valerolactone precursor for the synthesis of statins via lactonized side-chain. Synlett, 2009, 1144-1148.
94. Kathawala, F.G. Analogs of mevalolactone and derivatives thereof and their use as pharmaceuticals. PCT Pat. Appl. WO 84/02131, June 7, 1984.
95. Fuenfschilling, P.C.; Hoehn, P.; Mutz, J.-P. An improved manufacturing process for fluvastatin. Org. Process Res. Dev., 2007, 11, 13-18.
96. ®). J. Labeled Compd. Radiopharm., 1998, 41, 1-7.
97. Grabarkiewicz, T.; Grobelny, P.; Hoffmann, M., Mielcarek J. DFT study on hydroxy acid-lactone interconversion of statins: the case of fluvastatin. Org. Biomol. Chem., 2006, 4, 4299-4306.
98. Pandey, P.S.; Rao, T.S. An efficient synthesis of N3,4-diphenyl-5-(4- fluorophenyl)-2-isopropyl-1H-3-pyrrolecarboxamide, a key intermediate for atorvastatin synthesis. Bioorg. Med. Chem. Lett., 2004, 14, 129-131.
99. Roth, B.D.; Blankley, C.J.; Chucholowski, A.W.; Ferguson, E.; Hoefle, M.L.; Ortwine, D.F.; Newton, R.S.; Sekerke, C.S.; Sliskovic, D.R.; Stratton, C.D.; Wilson, M.W. Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4- hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG- CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus. J. Med. Chem., 1991, 34, 357-366.
100. 14C6]atorvastatin. J. Labeled Compd. Radiopharm., 1999, 42, 121-127.
101. Lee, H.T.; Woo, P.W.K. Atorvastatin, an HMG-COA reductase inhibitor and effective lipid-regulating agent. Part II. Synthesis of side-chain-labeled [14C]atorvastatin. J. Labeled Compd. Radiopharm., 1999, 42, 129-133.
102. Hoffmann, M.; Nowosielski, M. DFT study on hydroxy acid-lactone inter- conversion of statins: the case of atorvastatin. Org. Biomol. Chem., 2008, 6, 3527-3531.
103. Watanabe, M.; Koike, H.; Ishiba, T.; Okada, T.; Sea, S.; Hirai, K. Synthesis and biological activity of methanesulfonamide pyrimidine- and N- methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg. Med. Chem., 1997, 5, 437-444.
104. Andrushko, N.; Andrushko, V.; König, G.; Spannenberg, A., Börner, A. A new approach to the total synthesis of rosuvastatin. Eur. J. Org. Chem., 2008, 847-853.
105. Veith, U. Process for preparing 2-amino-4-(4-fluorophenyl)-6- alkylpyrimidine-5-carboxylates. PCT Pat. Appl. WO 01/04100, January 18, 2001.
106. Matsushita, A.; Oda, M.; Kawachi, Y.; Chika, J. Process for preparing aminopyrimidine compounds. PCT Pat. Appl. WO 2003/006439, January 23, 2003.
107. Brieden, W.; Veith, U. Process for the preparation of N-[5- (diphenylphosphinoylmethyl)-4-(4-fluorphenyl)-6-isopropylpyrimidin-2-yl]- N-methylmethansulfonamide. Euro Pat. Appl. EP 1035127, March 9, 2000.
108. Koike, H.; Kabaki, M.; Taylor, N.P.; Diorazio, L.J. Process for the production of tert-butyl (E)-(6- [2-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl]vinyl](4R, 6S)-2,2-dimethyl [1,3]dioxan-4-yl) acetate. PCT Pat. Appl. WO 2000/049014, August 24, 2000.
109. Butters, M.; Cox, D.K.; Crabb, J.N.; Lenger, S.R.; Murray, P.M.; Snape, E.W. Processes for the manufacture of rosuvastatin and intermediates. PCT Pat. Appl. WO 2007/007119, January 18, 2007.
110. Butters, M.; Lenger, S.R.; Murray, P.M.; Snape, E.W. Process for the manufacture of (E)-7- [4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl) amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid (rosuvastatin). PCT Pat. Appl. WO 2006/067456, June 29, 2006.
111. Joshi, N.; Bhirud, S.B.; Chandrasekhar, B.; Rao, K.E.; Damle, S. An improved process for preparation of rosuvastatin derivatives, useful as HMG- CoA inhibitor. U.S. Pat. Appl. US 2005/124639, June 9, 2005.
112. Satyanarayana Reddy, M.; Thirumalai Rajan, S.; Sahadeva Reddy, M. Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof. PCT Pat. Appl. WO 2008/044243, April 17, 2008.
113. Huang, Q. Method for preparation of 4-(fluorophenyl)-6-isopropyl-2-(N- methyl-N-methylsulfonylamino)-5-formyl-pyrimidine. PCT Pat. Appl. WO 2008/151510, December 18, 2008.
114. Dandala, R.; Mallela, S.P.S.; Garimella, N.K.A.S.S.; Nandi, S.; Buridipad, S.K.; Nangi, G.B.S.; Meenakshisunderam, S. A process for preparing rosuvastatin calcium. PCT Pat. Appl. WO 2008/053334, May 8, 2008.
115. Deshpande, P.B.; Ramakrishnan, A.; Nilesh, B.S.; Ranjit, A.G. Process for preparation of Rosuvastatin and its calcium salt. PCT Pat. Appl. WO 2006/100689, September 28, 2006.
116. Huang, Q. Process for preparation of Rosuvastatin calcium. PCT Pat. Appl. WO 2006/076845, July 27, 2006.
117. Sliskovic, D.R.; Picard, J.A.; Roark, W.H.; Roth, B.D.; Ferguson, E.; Krause, B.R.; Newton, R.S.; Sekerke, C.; Shaw, M.K. Inhibitors of cholesterol bio- synthesis. 4. trans-6- [2-(Substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4- hydroxy-2H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors. J. Med. Chem., 1991, 34, 367-373.
118. Miyachi, N.; Yanagawa, Y.; Iwasaki, H.; Ohara, Y.; Hiyama, T. A novel synthetic method of HMG-CoA reductase inhibitor NK-104 via a hydrobora- tion-cross coupling sequence. Tetrahedron Lett., 1993, 34, 8267-8270.
119. Suzuki, M.; Tanikawa, K.; Sakoda, R. Practical synthesis of quinoline nucleus of NK-104. Heterocycles, 1999, 50, 479-483.
120. Suzuki, M.; Iwasaki, H.; Fujikawa, Y.; Kitahara, M.; Sakashita, M.; Sakoda, R. Synthesis and biological evaluations of quinoline-based HMG-CoA re- ductase inhibitors. Bioorg. Med. Chem., 2001, 9, 2727-2743.
121. Hiyama, T.; Minami, T.; Takahashi, K. Synthesis of artificial HMG-CoA reductase inhibitors based on the olefination strategy. Bull. Chem. Soc. Jpn., 1995, 68, 364-372.
122. Nagashima, K.; Fukumoto, T.; Hayashibara, T.; Torihara, M. Process for preparation of quinolinecarbaldehyde derivatives. PCT Pat. Appl. WO 2004/041787, May 21, 2004.
123. Jia, C.-S.; Wang, G.-W. Efficient solvent-free synthesis of quinolines promoted by BiCl3. Lett. Org. Chem., 2006, 3, 289-291.
124. Jia, C.-S.; Zhang, Z.; Tu, S.-J.; Wang, G.-W. Rapid and efficient synthesis of poly-substituted quinolines assisted by p-toluene sulphonic acid under sol- vent-free conditions: comparative study of microwave irradiation versus conventional heating. Org. Biomol. Chem., 2006, 4, 104-110.
125. Suzuki, M.; Yanagawa, Y.; Iwasaki, H.; Kanda, H.; Yanagihara, K.; Matsumoto, H.; Ohara, Y.; Yazaki, Y.; Sakoda, R. First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104. Bioorg. Med. Chem. Lett., 1999, 9, 2977-2982.
126. Chen, G.-P.; Kapa, P.K.; Loeser, E.M.; Beutler, U.; Zaugg, W.; Girgis, M.J. Process for the manufacture of organic compounds. PCT Pat. Appl. WO 2003/064382, August 7, 2003.
127. Minami, T.; Hiyama, T. A novel enantioselective synthesis of HMG Co-A reductase inhibitor NK-104 and a related compound. Tetrahedron Lett., 1992, 33, 7525-7526.
128. Hiyama, T.; Minami, T.; Yanagawa, Y.; Ohara, Y. Condensed pyridine type mevalonolactone intermediate and process for its production. PCT Pat. Appl. WO 95/11898, May 4, 1995.
129. Takahashi, K.; Minami, T.; Ohara, Y.; Hiyama, T. A new synthesis of HMG- CoA reductase inhibitor NK-104 through hydrosilylation-cross coupling re- action. Tetrahedron Lett., 1993, 34, 8263-8266.
130. Takano, S.; Kamikubo, T.; Sugihara, T.; Suzuki, M.; Ogasawara, K. Enantio- convergent synthesis of a promising HMG Co-A reductase inhibitor NK-104 from both enantiomers of epichlorohydrin. Tetrahedron Asymmetry, 1993, 4, 201-204.
131. Ma, S.K.; Gruber, J.; Davis, C.; Newman, L.; Gray, D.; Wang, A.; Grate, J.; Huisman, G.W.; Sheldon R.A. A green-by-design biocatalytic process for atorvastatin intermediate. Green Chem., 2010, 12, 81-86.